Pediatrics
-
Review Meta Analysis
Prophylactic Early Erythropoietin for Neuroprotection in Preterm Infants: A Meta-analysis.
Recombinant human erythropoietin (rhEPO) is a promising pharmacological agent for neuroprotection in neonates. ⋯ Prophylactic rhEPO improved the cognitive development of very preterm infants, as assessed by the MDI at a corrected age of 18 to 24 months, without affecting other neurodevelopmental outcomes. Current and future RCTs should investigate optimal dosing and timing of prophylactic rhEPO and plan for long-term neurodevelopmental follow-up.